Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s share price was up 10.5% on Wednesday . The company traded as high as $7.11 and last traded at $7.08. Approximately 19,784 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 86,861 shares. The stock had previously closed at $6.41.
Wall Street Analysts Forecast Growth
Separately, Noble Financial initiated coverage on Gyre Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating on the stock.
Read Our Latest Report on GYRE
Gyre Therapeutics Stock Up 2.3 %
The firm has a market capitalization of $662.77 million, a PE ratio of 140.82 and a beta of 2.03. The stock has a 50-day moving average price of $10.77 and a 200 day moving average price of $11.83.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its quarterly earnings results on Monday, March 17th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.03). Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%. The company had revenue of $27.87 million for the quarter, compared to analyst estimates of $23.50 million.
Institutional Trading of Gyre Therapeutics
Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock valued at $3,808,000 after purchasing an additional 43,840 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Gyre Therapeutics by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company's stock valued at $1,386,000 after buying an additional 918 shares during the last quarter. State Street Corp lifted its stake in shares of Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after buying an additional 8,412 shares in the last quarter. Northern Trust Corp boosted its position in Gyre Therapeutics by 9.1% during the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company's stock worth $1,251,000 after acquiring an additional 8,624 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in Gyre Therapeutics during the 4th quarter valued at about $1,225,000. 23.99% of the stock is owned by institutional investors and hedge funds.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
